Recent News

• 07.23.2026 - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
• 07.23.2026 - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
• 07.23.2026 - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
• 07.14.2026 - Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
• 07.14.2026 - Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
• 07.14.2026 - Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
• 07.02.2026 - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.02.2026 - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.02.2026 - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.12.2026 - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Recent Filings

• 07.23.2026 - 8-K Current report
• 07.23.2026 - EX-99.1 EX-99.1
• 07.17.2026 - 3 Initial statement of beneficial ownership of securities
• 07.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.14.2026 - 8-K Current report
• 07.14.2026 - EX-99.1 EX-99.1
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 4 Statement of changes in beneficial ownership of securities